Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center in Buffalo, NY, shares a brief overview of AML and discusses how the treatment landscape for patients with AML has changed in recent years.
Click here to learn more.
In this update, Ashley Yocum, PhD, executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society, provides insights into the Beat AML…
Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial…
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome…
In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of…
